Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients | Zendy

Medha Airy | Zendy; Sreedhar Mandayam | Zendy; Aya Mitani | Zendy; Tara I. Chang | Zendy; Victoria Y. Ding | Zendy; M. Alan Brookhart | Zendy; Benjamin A. Goldstein | Zendy; Wolfgang C. Winkelmayer­ | Zendy

Open Access

Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients

Author(s) -

Medha Airy,

Sreedhar Mandayam,

Aya Mitani,

Tara I. Chang,

Victoria Y. Ding,

M. Alan Brookhart,

Benjamin A. Goldstein,

Wolfgang C. Winkelmayer

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv305

Subject(s) - medicine , ferumoxytol , hemodialysis , intravenous iron , iron sucrose , anemia , end stage renal disease , surgery , iron deficiency , radiology , magnetic resonance imaging

Ferumoxytol was first approved for clinical use in 2009 solely based on data from trial comparisons with oral iron on biochemical anemia efficacy end points. To compare the rates of important patient outcomes (infection, cardiovascular events and death) between facilities predominantly using ferumoxytol versus iron sucrose (IS) or ferric gluconate (FG) in patients with end-stage renal disease (ESRD)-initiating hemodialysis (HD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research